Does ATEZOLIZUMAB Cause Interstitial lung disease? 731 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 731 reports of Interstitial lung disease have been filed in association with ATEZOLIZUMAB (Tecentriq Hybreza). This represents 2.2% of all adverse event reports for ATEZOLIZUMAB.
731
Reports of Interstitial lung disease with ATEZOLIZUMAB
2.2%
of all ATEZOLIZUMAB reports
160
Deaths
305
Hospitalizations
How Dangerous Is Interstitial lung disease From ATEZOLIZUMAB?
Of the 731 reports, 160 (21.9%) resulted in death, 305 (41.7%) required hospitalization, and 38 (5.2%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for ATEZOLIZUMAB.
What Other Side Effects Does ATEZOLIZUMAB Cause?
Death (3,591)
Off label use (2,340)
Disease progression (1,828)
Pyrexia (1,599)
Diarrhoea (1,490)
Fatigue (1,253)
Anaemia (1,195)
Pneumonia (1,036)
Nausea (953)
Dyspnoea (938)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which ATEZOLIZUMAB Alternatives Have Lower Interstitial lung disease Risk?
ATEZOLIZUMAB vs ATLANTIC SALMON OIL
ATEZOLIZUMAB vs ATOGEPANT
ATEZOLIZUMAB vs ATOMOXETINE
ATEZOLIZUMAB vs ATOMOXETINE\ATOMOXETINE
ATEZOLIZUMAB vs ATORVASTATIN